158 results on '"Pérez Encinas, M."'
Search Results
2. 5PSQ-012 Case report: Inhaled granulocyte-macrophage colony-stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis – 24 months of follow-up
3. 4CPS-260 Persistence, safety and associated lymphopenia of dimethyl fumarate in relapsing remitting multiple sclerosis, real world data
4. P1032: REAL-LIFE VALIDATION OF MIPSS70: A RETROSPECTIVE MULTICENTER AND NGS ANALYSIS FROM THE GEMFIN DATABASE
5. P1001: DNMT3A/TET2/ASXL1 MUTATIONS DETERMINE THROMBOTIC RISK IN POLYCYTHAEMIA VERA
6. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
7. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method
8. Intervención farmacéutica en la adherencia al tratamiento de pacientes con enfermedad renal crónica
9. 2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments
10. 4CPS-333 Treating multiple sclerosis patients with infusion of disease modifying treatments during the COVID-19 pandemic
11. 5PSQ-221 Safety profile of experimental therapies used in the COVID-19 pandemic based on data from the National Minimum Data Set
12. SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments
13. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
14. Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry
15. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses
16. Comparison of the traditional pharmaceutical validation method versus an assisted pharmaceutical validation in hospitalized patients
17. Essential thrombocythaemia with mutation in MPL : clinicopathological correlation and comparison with JAK 2V617F-mutated and CALR- mutated genotypes
18. PF419 ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS)
19. 5PSQ-023 Adequate digoxin dosage in patients with digitalis toxicity
20. 4CPS-182 Experience with omalizumab in the treatment of uncontrolled persistent asthma
21. 5PSQ-044 Aseptic meningitis induced by intravenous immunoglobulin
22. 4CPS-191 Effectiveness and safety of radium-223 chloride in bone-metastatic castration-resistant prostate cancer
23. Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia
24. Comparison of the traditional pharmaceutical validation method versus an assisted pharmaceutical validation in hospitalized patients
25. Oral formulation of pyridoxine for the treatment of pyridoxine-dependent epilepsy in a paediatric patient
26. A prognostic model for survival after salvage treatment with FLAG-Ida plus /- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
27. Evaluación de las prácticas de seguridad de los sistemas de utilización de medicamentos en los hospitales españoles (2007)
28. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
29. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
30. Oclusión arterial asociada a la interacción entre ritonavir y ergotamina en paciente VIH
31. Oclusión arterial asociada a la interacción entre ritonavir y ergotamina en paciente VIH
32. CP-116 Appropriateness of ticagrelor and prasugrel use after the implementation of an antiplatelet protocol in acute coronary syndrome
33. PCN298 - The Clinical and Economic Burden of Skeletal Related Events in Austria, Czech Republic, Germany, Greece, Italy, Spain and Switzerland: a Comparison Between the use of Denosumab and Zoledronic Acid In Patients with Prostate Cancer And Bone Metastases
34. PCN299 - The Clinical and Economic Burden of Skeletal Related Events in Austria, Czech Republic, Germany, Greece, Italy, Spain and Switzerland: A Comparison Between the use of Denosumab and Zoledronic acid in Patients With Breast Cancer and Bone Metastases
35. Acidosis metabólica y anemia severas relacionadas con linezolid
36. Evaluación de las prácticas de seguridad de los sistemas de utilización de medicamentos en los hospitales españoles (2007)
37. Linfomas orbitarios: Presentación de nueve casos
38. Sindrome neuroléptico maligno asociado a antidepresivos tricíclicos
39. Linfoma primario hepático. implicaciones diagnósticas y terapéuticas
40. Correlation and Prognostic Value of Serum Soluble ICAM-1, Beta-2 Microglobulin, and IL-2αR Levels in Non-Hodgkin's Lymphoma
41. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
42. Multicriteria decision analysis for determining drug therapy for intermittent claudication
43. Familial myeloproliferative syndrome
44. Screening of JAK2 V617F Mutation in 84 Patients with Thrombocythemia and Erythrocytosis. Is Necesary for Diagnosis of a Chronic Myeloproliferative Disorders?.
45. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
46. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
47. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
48. DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.
49. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
50. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.